Drugs / ACM-CpG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07658196 | Jul 2026 → Jul 2028 expected | appendix adenocarcinoma, peritoneal carcinomatosis | Brown University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06587295 | Jan 2025 → Dec 2026 expected | metastatic malignant neoplasm | National Cancer Centre, Singapore | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | ACM Biolabs | Results ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors acmbiolabs.com ↗
Early clinical data indicate that these preclinical findings are translating into humans. |
All press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACM-CpG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07658196 ↗ |
| Action | Activate | “ACM-CpG is a CpG-B TLR9 agonist” NCT06587295 ↗ |
| Route | Intramuscular | “Dose escalation for ACM-CpG monotherapy administered via intramuscular injection” NCT06587295 ↗ |
| Target | TLR9 | “ACM-CpG is a CpG-B TLR9 agonist” NCT06587295 ↗ |